Exagen INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

11 Mar 2025

XGN

10-K: Exagen Inc. Reports Fiscal Year 2024 Results: Revenue Growth and Strategic Pipeline Expansion

Exagen Inc. demonstrates revenue growth, margin expansion, and strategic pipeline development in its fiscal year 2024 results, positioning itself for near-term profitability.

NASDAQ

18 Mar 2024

XGN

Exagen INC

10-K: Exagen Inc. Reports 15.3% Revenue Growth in 2023, Driven by AVISE CTD Test Adoption and Reimbursement Improvements

Exagen Inc., a diagnostics company specializing in autoimmune diseases, announced a 15.3% increase in revenue for 2023, reaching $52.5 million, primarily attributed to the increased adoption of its flagship AVISE CTD test and improved commercial payor average selling price (ASP).